1
|
Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD, Amanatides P, Ballew RM, Huson DH, Wortman JR, Zhang Q, Kodira CD, Zheng XH, Chen L, Skupski M, Subramanian G, Thomas PD, Zhang J, Gabor Miklos GL, Nelson C, Broder S, Clark AG, Nadeau J, McKusick VA, Zinder N, Levine AJ, Roberts RJ, Simon M, Slayman C, Hunkapiller M, Bolanos R, Delcher A, Dew I, Fasulo D, Flanigan M, Florea L, Halpern A, Hannenhalli S, Kravitz S, Levy S, Mobarry C, Reinert K, Remington K, Abu-Threideh J, Beasley E, Biddick K, Bonazzi V, Brandon R, Cargill M, Chandramouliswaran I, Charlab R, Chaturvedi K, Deng Z, Di Francesco V, Dunn P, Eilbeck K, Evangelista C, Gabrielian AE, Gan W, Ge W, Gong F, Gu Z, Guan P, Heiman TJ, Higgins ME, Ji RR, Ke Z, Ketchum KA, Lai Z, Lei Y, Li Z, Li J, Liang Y, Lin X, Lu F, Merkulov GV, Milshina N, Moore HM, Naik AK, Narayan VA, Neelam B, Nusskern D, Rusch DB, Salzberg S, Shao W, Shue B, Sun J, Wang Z, Wang A, Wang X, Wang J, Wei M, Wides R, Xiao C, Yan C, Yao A, Ye J, Zhan M, Zhang W, Zhang H, Zhao Q, Zheng L, Zhong F, Zhong W, Zhu S, Zhao S, Gilbert D, Baumhueter S, Spier G, Carter C, Cravchik A, Woodage T, Ali F, An H, Awe A, Baldwin D, Baden H, Barnstead M, Barrow I, Beeson K, Busam D, Carver A, Center A, Cheng ML, Curry L, Danaher S, Davenport L, Desilets R, Dietz S, Dodson K, Doup L, Ferriera S, Garg N, Gluecksmann A, Hart B, Haynes J, Haynes C, Heiner C, Hladun S, Hostin D, Houck J, Howland T, Ibegwam C, Johnson J, Kalush F, Kline L, Koduru S, Love A, Mann F, May D, McCawley S, McIntosh T, McMullen I, Moy M, Moy L, Murphy B, Nelson K, Pfannkoch C, Pratts E, Puri V, Qureshi H, Reardon M, Rodriguez R, Rogers YH, Romblad D, Ruhfel B, Scott R, Sitter C, Smallwood M, Stewart E, Strong R, Suh E, Thomas R, Tint NN, Tse S, Vech C, Wang G, Wetter J, Williams S, Williams M, Windsor S, Winn-Deen E, Wolfe K, Zaveri J, Zaveri K, Abril JF, Guigó R, Campbell MJ, Sjolander KV, Karlak B, Kejariwal A, Mi H, Lazareva B, Hatton T, Narechania A, Diemer K, Muruganujan A, Guo N, Sato S, Bafna V, Istrail S, Lippert R, Schwartz R, Walenz B, Yooseph S, Allen D, Basu A, Baxendale J, Blick L, Caminha M, Carnes-Stine J, Caulk P, Chiang YH, Coyne M, Dahlke C, Deslattes Mays A, Dombroski M, Donnelly M, Ely D, Esparham S, Fosler C, Gire H, Glanowski S, Glasser K, Glodek A, Gorokhov M, Graham K, Gropman B, Harris M, Heil J, Henderson S, Hoover J, Jennings D, Jordan C, Jordan J, Kasha J, Kagan L, Kraft C, Levitsky A, Lewis M, Liu X, Lopez J, Ma D, Majoros W, McDaniel J, Murphy S, Newman M, Nguyen T, Nguyen N, Nodell M, Pan S, Peck J, Peterson M, Rowe W, Sanders R, Scott J, Simpson M, Smith T, Sprague A, Stockwell T, Turner R, Venter E, Wang M, Wen M, Wu D, Wu M, Xia A, Zandieh A, Zhu X. The sequence of the human genome. Science 2001; 291:1304-51. [PMID: 11181995 DOI: 10.1126/science.1058040] [Citation(s) in RCA: 7820] [Impact Index Per Article: 325.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A 2.91-billion base pair (bp) consensus sequence of the euchromatic portion of the human genome was generated by the whole-genome shotgun sequencing method. The 14.8-billion bp DNA sequence was generated over 9 months from 27,271,853 high-quality sequence reads (5.11-fold coverage of the genome) from both ends of plasmid clones made from the DNA of five individuals. Two assembly strategies-a whole-genome assembly and a regional chromosome assembly-were used, each combining sequence data from Celera and the publicly funded genome effort. The public data were shredded into 550-bp segments to create a 2.9-fold coverage of those genome regions that had been sequenced, without including biases inherent in the cloning and assembly procedure used by the publicly funded group. This brought the effective coverage in the assemblies to eightfold, reducing the number and size of gaps in the final assembly over what would be obtained with 5.11-fold coverage. The two assembly strategies yielded very similar results that largely agree with independent mapping data. The assemblies effectively cover the euchromatic regions of the human chromosomes. More than 90% of the genome is in scaffold assemblies of 100,000 bp or more, and 25% of the genome is in scaffolds of 10 million bp or larger. Analysis of the genome sequence revealed 26,588 protein-encoding transcripts for which there was strong corroborating evidence and an additional approximately 12,000 computationally derived genes with mouse matches or other weak supporting evidence. Although gene-dense clusters are obvious, almost half the genes are dispersed in low G+C sequence separated by large tracts of apparently noncoding sequence. Only 1.1% of the genome is spanned by exons, whereas 24% is in introns, with 75% of the genome being intergenic DNA. Duplications of segmental blocks, ranging in size up to chromosomal lengths, are abundant throughout the genome and reveal a complex evolutionary history. Comparative genomic analysis indicates vertebrate expansions of genes associated with neuronal function, with tissue-specific developmental regulation, and with the hemostasis and immune systems. DNA sequence comparisons between the consensus sequence and publicly funded genome data provided locations of 2.1 million single-nucleotide polymorphisms (SNPs). A random pair of human haploid genomes differed at a rate of 1 bp per 1250 on average, but there was marked heterogeneity in the level of polymorphism across the genome. Less than 1% of all SNPs resulted in variation in proteins, but the task of determining which SNPs have functional consequences remains an open challenge.
Collapse
|
|
24 |
7820 |
2
|
Abbott BP, Abbott R, Abbott TD, Abernathy MR, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allocca A, Altin PA, Anderson SB, Anderson WG, Arai K, Arain MA, Araya MC, Arceneaux CC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Aufmuth P, Aulbert C, Babak S, Bacon P, Bader MKM, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Barayoga JC, Barclay SE, Barish BC, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Barton MA, Bartos I, Bassiri R, Basti A, Batch JC, Baune C, Bavigadda V, Bazzan M, Behnke B, Bejger M, Belczynski C, Bell AS, Bell CJ, Berger BK, Bergman J, Bergmann G, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Birch J, Birney R, Birnholtz O, Biscans S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bodiya TP, Boer M, Bogaert G, Bogan C, Bohe A, Bojtos P, Bond C, Bondu F, Bonnand R, Boom BA, Bork R, Boschi V, Bose S, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brau JE, Briant T, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks AF, Brown DA, Brown DD, Brown NM, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister T, Calloni E, Camp JB, Cannon KC, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerboni Baiardi L, Cerretani G, Cesarini E, Chakraborty R, Chalermsongsak T, Chamberlin SJ, Chan M, Chao S, Charlton P, Chassande-Mottin E, Chen HY, Chen Y, Cheng C, Chincarini A, Chiummo A, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua S, Chung S, Ciani G, Clara F, Clark JA, Cleva F, Coccia E, Cohadon PF, Colla A, Collette CG, Cominsky L, Constancio M, Conte A, Conti L, Cook D, Corbitt TR, Cornish N, Corsi A, Cortese S, Costa CA, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Craig K, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cruise AM, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Danilishin SL, D'Antonio S, Danzmann K, Darman NS, Da Silva Costa CF, Dattilo V, Dave I, Daveloza HP, Davier M, Davies GS, Daw EJ, Day R, De S, DeBra D, Debreczeni G, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Denker T, Dent T, Dereli H, Dergachev V, DeRosa RT, De Rosa R, DeSalvo R, Dhurandhar S, Díaz MC, Di Fiore L, Di Giovanni M, Di Lieto A, Di Pace S, Di Palma I, Di Virgilio A, Dojcinoski G, Dolique V, Donovan F, Dooley KL, Doravari S, Douglas R, Downes TP, Drago M, Drever RWP, Driggers JC, Du Z, Ducrot M, Dwyer SE, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Engels W, Essick RC, Etzel T, Evans M, Evans TM, Everett R, Factourovich M, Fafone V, Fair H, Fairhurst S, Fan X, Fang Q, Farinon S, Farr B, Farr WM, Favata M, Fays M, Fehrmann H, Fejer MM, Feldbaum D, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Finn LS, Fiori I, Fiorucci D, Fisher RP, Flaminio R, Fletcher M, Fong H, Fournier JD, Franco S, Frasca S, Frasconi F, Frede M, Frei Z, Freise A, Frey R, Frey V, Fricke TT, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard HAG, Gair JR, Gammaitoni L, Gaonkar SG, Garufi F, Gatto A, Gaur G, Gehrels N, Gemme G, Gendre B, Genin E, Gennai A, George J, Gergely L, Germain V, Ghosh A, Ghosh A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gill K, Glaefke A, Gleason JR, Goetz E, Goetz R, Gondan L, González G, Gonzalez Castro JM, Gopakumar A, Gordon NA, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Graef C, Graff PB, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Greenhalgh RJS, Groot P, Grote H, Grunewald S, Guidi GM, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Hacker JJ, Hall BR, Hall ED, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Hartman MT, Haster CJ, Haughian K, Healy J, Heefner J, Heidmann A, Heintze MC, Heinzel G, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Heurs M, Hild S, Hoak D, Hodge KA, Hofman D, Hollitt SE, Holt K, Holz DE, Hopkins P, Hosken DJ, Hough J, Houston EA, Howell EJ, Hu YM, Huang S, Huerta EA, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Idrisy A, Indik N, Ingram DR, Inta R, Isa HN, Isac JM, Isi M, Islas G, Isogai T, Iyer BR, Izumi K, Jacobson MB, Jacqmin T, Jang H, Jani K, Jaranowski P, Jawahar S, Jiménez-Forteza F, Johnson WW, Johnson-McDaniel NK, Jones DI, Jones R, Jonker RJG, Ju L, Haris K, Kalaghatgi CV, Kalogera V, Kandhasamy S, Kang G, Kanner JB, Karki S, Kasprzack M, Katsavounidis E, Katzman W, Kaufer S, Kaur T, Kawabe K, Kawazoe F, Kéfélian F, Kehl MS, Keitel D, Kelley DB, Kells W, Kennedy R, Keppel DG, Key JS, Khalaidovski A, Khalili FY, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim J, Kim K, Kim NG, Kim N, Kim YM, King EJ, King PJ, Kinzel DL, Kissel JS, Kleybolte L, Klimenko S, Koehlenbeck SM, Kokeyama K, Koley S, Kondrashov V, Kontos A, Koranda S, Korobko M, Korth WZ, Kowalska I, Kozak DB, Kringel V, Krishnan B, Królak A, Krueger C, Kuehn G, Kumar P, Kumar R, Kuo L, Kutynia A, Kwee P, Lackey BD, Landry M, Lange J, Lantz B, Lasky PD, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lebigot EO, Lee CH, Lee HK, Lee HM, Lee K, Lenon A, Leonardi M, Leong JR, Leroy N, Letendre N, Levin Y, Levine BM, Li TGF, Libson A, Littenberg TB, Lockerbie NA, Logue J, Lombardi AL, London LT, Lord JE, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lundgren AP, Luo J, Lynch R, Ma Y, MacDonald T, Machenschalk B, MacInnis M, Macleod DM, Magaña-Sandoval F, Magee RM, Mageswaran M, Majorana E, Maksimovic I, Malvezzi V, Man N, Mandel I, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markosyan AS, Maros E, Martelli F, Martellini L, Martin IW, Martin RM, Martynov DV, Marx JN, Mason K, Masserot A, Massinger TJ, Masso-Reid M, Matichard F, Matone L, Mavalvala N, Mazumder N, Mazzolo G, McCarthy R, McClelland DE, McCormick S, McGuire SC, McIntyre G, McIver J, McManus DJ, McWilliams ST, Meacher D, Meadors GD, Meidam J, Melatos A, Mendell G, Mendoza-Gandara D, Mercer RA, Merilh E, Merzougui M, Meshkov S, Messenger C, Messick C, Meyers PM, Mezzani F, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller J, Millhouse M, Minenkov Y, Ming J, Mirshekari S, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moggi A, Mohan M, Mohapatra SRP, Montani M, Moore BC, Moore CJ, Moraru D, Moreno G, Morriss SR, Mossavi K, Mours B, Mow-Lowry CM, Mueller CL, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Murphy DJ, Murray PG, Mytidis A, Nardecchia I, Naticchioni L, Nayak RK, Necula V, Nedkova K, Nelemans G, Neri M, Neunzert A, Newton G, Nguyen TT, Nielsen AB, Nissanke S, Nitz A, Nocera F, Nolting D, Normandin MEN, Nuttall LK, Oberling J, Ochsner E, O'Dell J, Oelker E, Ogin GH, Oh JJ, Oh SH, Ohme F, Oliver M, Oppermann P, Oram RJ, O'Reilly B, O'Shaughnessy R, Ott CD, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pan Y, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Paris HR, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patricelli B, Patrick Z, Pearlstone BL, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perreca A, Pfeiffer HP, Phelps M, Piccinni O, Pichot M, Pickenpack M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pitkin M, Poeld JH, Poggiani R, Popolizio P, Post A, Powell J, Prasad J, Predoi V, Premachandra SS, Prestegard T, Price LR, Prijatelj M, Principe M, Privitera S, Prix R, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Qin J, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rakhmanov M, Ramet CR, Rapagnani P, Raymond V, Razzano M, Re V, Read J, Reed CM, Regimbau T, Rei L, Reid S, Reitze DH, Rew H, Reyes SD, Ricci F, Riles K, Robertson NA, Robie R, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano JD, Romano R, Romanov G, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Sachdev S, Sadecki T, Sadeghian L, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sandberg V, Sandeen B, Sanders GH, Sanders JR, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Schilling R, Schmidt J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schutz BF, Scott J, Scott SM, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Serna G, Setyawati Y, Sevigny A, Shaddock DA, Shaffer T, Shah S, Shahriar MS, Shaltev M, Shao Z, Shapiro B, Shawhan P, Sheperd A, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sigg D, Silva AD, Simakov D, Singer A, Singer LP, Singh A, Singh R, Singhal A, Sintes AM, Slagmolen BJJ, Smith JR, Smith MR, Smith ND, Smith RJE, Son EJ, Sorazu B, Sorrentino F, Souradeep T, Srivastava AK, Staley A, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stephens BC, Stevenson SP, Stone R, Strain KA, Straniero N, Stratta G, Strauss NA, Strigin S, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Talukder D, Tanner DB, Tápai M, Tarabrin SP, Taracchini A, Taylor R, Theeg T, Thirugnanasambandam MP, Thomas EG, Thomas M, Thomas P, Thorne KA, Thorne KS, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Tomlinson C, Tonelli M, Torres CV, Torrie CI, Töyrä D, Travasso F, Traylor G, Trifirò D, Tringali MC, Trozzo L, Tse M, Turconi M, Tuyenbayev D, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Vass S, Vasúth M, Vaulin R, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Verkindt D, Vetrano F, Viceré A, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Voss D, Vousden WD, Vyatchanin SP, Wade AR, Wade LE, Wade M, Waldman SJ, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang M, Wang X, Wang Y, Ward H, Ward RL, Warner J, Was M, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Welborn T, Wen L, Weßels P, Westphal T, Wette K, Whelan JT, Whitcomb SE, White DJ, Whiting BF, Wiesner K, Wilkinson C, Willems PA, Williams L, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkelmann L, Winkler W, Wipf CC, Wiseman AG, Wittel H, Woan G, Worden J, Wright JL, Wu G, Yablon J, Yakushin I, Yam W, Yamamoto H, Yancey CC, Yap MJ, Yu H, Yvert M, Zadrożny A, Zangrando L, Zanolin M, Zendri JP, Zevin M, Zhang F, Zhang L, Zhang M, Zhang Y, Zhao C, Zhou M, Zhou Z, Zhu XJ, Zucker ME, Zuraw SE, Zweizig J. Observation of Gravitational Waves from a Binary Black Hole Merger. PHYSICAL REVIEW LETTERS 2016; 116:061102. [PMID: 26918975 DOI: 10.1103/physrevlett.116.061102] [Citation(s) in RCA: 1423] [Impact Index Per Article: 158.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Indexed: 05/04/2023]
Abstract
On September 14, 2015 at 09:50:45 UTC the two detectors of the Laser Interferometer Gravitational-Wave Observatory simultaneously observed a transient gravitational-wave signal. The signal sweeps upwards in frequency from 35 to 250 Hz with a peak gravitational-wave strain of 1.0×10(-21). It matches the waveform predicted by general relativity for the inspiral and merger of a pair of black holes and the ringdown of the resulting single black hole. The signal was observed with a matched-filter signal-to-noise ratio of 24 and a false alarm rate estimated to be less than 1 event per 203,000 years, equivalent to a significance greater than 5.1σ. The source lies at a luminosity distance of 410(-180)(+160) Mpc corresponding to a redshift z=0.09(-0.04)(+0.03). In the source frame, the initial black hole masses are 36(-4)(+5)M⊙ and 29(-4)(+4)M⊙, and the final black hole mass is 62(-4)(+4)M⊙, with 3.0(-0.5)(+0.5)M⊙c(2) radiated in gravitational waves. All uncertainties define 90% credible intervals. These observations demonstrate the existence of binary stellar-mass black hole systems. This is the first direct detection of gravitational waves and the first observation of a binary black hole merger.
Collapse
|
|
9 |
1423 |
3
|
Wang M, Lawal A, Stephenson P, Sidders J, Ramshaw C. Post-combustion CO2 capture with chemical absorption: A state-of-the-art review. Chem Eng Res Des 2011. [DOI: 10.1016/j.cherd.2010.11.005] [Citation(s) in RCA: 887] [Impact Index Per Article: 63.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
|
14 |
887 |
4
|
Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 1992; 66:6527-32. [PMID: 1328679 PMCID: PMC240146 DOI: 10.1128/jvi.66.11.6527-6532.1992] [Citation(s) in RCA: 652] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Norwalk virus capsid protein was produced by expression of the second and third open reading frames of the Norwalk virus genome, using a cell-free translation system and baculovirus recombinants. Analysis of the expressed products showed that the second open reading frame encodes a protein with an apparent molecular weight of 58,000 (58K protein) and that this protein self-assembles to form empty viruslike particles similar to native capsids in size and appearance. The antigenicity of these particles was demonstrated by immunoprecipitation and enzyme-linked immunosorbent assays of paired serum samples from volunteers who developed illness following Norwalk virus challenge. These particles also induced high levels of Norwalk virus-specific serum antibody in laboratory animals following parenteral inoculation. A minor 34K protein was also found in infected insect cells. Amino acid sequence analysis of the N terminus of the 34K protein indicated that the 34K protein was a cleavage product of the 58K protein. The availability of large amounts of recombinant Norwalk virus particles will allow the development of rapid, sensitive, and reliable tests for the diagnosis of Norwalk virus infection as well as the implementation of structural studies.
Collapse
|
research-article |
33 |
652 |
5
|
Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892-905. [PMID: 11602729 PMCID: PMC114669 DOI: 10.1128/jvi.75.22.10892-10905.2001] [Citation(s) in RCA: 641] [Impact Index Per Article: 26.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2001] [Accepted: 07/30/2001] [Indexed: 11/20/2022] Open
Abstract
The identification and epitope mapping of broadly neutralizing anti-human immunodeficiency virus type 1 (HIV-1) antibodies (Abs) is important for vaccine design, but, despite much effort, very few such Abs have been forthcoming. Only one broadly neutralizing anti-gp41 monoclonal Ab (MAb), 2F5, has been described. Here we report on two MAbs that recognize a region immediately C-terminal of the 2F5 epitope. Both MAbs were generated from HIV-1-seropositive donors, one (Z13) from an antibody phage display library, and one (4E10) as a hybridoma. Both MAbs recognize a predominantly linear and relatively conserved epitope, compete with each other for binding to synthetic peptide derived from gp41, and bind to HIV-1(MN) virions. By flow cytometry, these MAbs appear to bind relatively weakly to infected cells and this binding is not perturbed by pretreatment of the infected cells with soluble CD4. Despite the apparent linear nature of the epitopes of Z13 and 4E10, denaturation of recombinant envelope protein reduces the binding of these MAbs, suggesting some conformational requirements for full epitope expression. Most significantly, Z13 and 4E10 are able to neutralize selected primary isolates from diverse subtypes of HIV-1 (e.g., subtypes B, C, and E). The results suggest that a rather extensive region of gp41 close to the transmembrane domain is accessible to neutralizing Abs and could form a useful target for vaccine design.
Collapse
|
research-article |
24 |
641 |
6
|
Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, Kim JJ. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci U S A 1997; 94:8411-6. [PMID: 9237990 PMCID: PMC22938 DOI: 10.1073/pnas.94.16.8411] [Citation(s) in RCA: 582] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Microsomal NADPH-cytochrome P450 reductase (CPR) is one of only two mammalian enzymes known to contain both FAD and FMN, the other being nitric-oxide synthase. CPR is a membrane-bound protein and catalyzes electron transfer from NADPH to all known microsomal cytochromes P450. The structure of rat liver CPR, expressed in Escherichia coli and solubilized by limited trypsinolysis, has been determined by x-ray crystallography at 2.6 A resolution. The molecule is composed of four structural domains: (from the N- to C- termini) the FMN-binding domain, the connecting domain, and the FAD- and NADPH-binding domains. The FMN-binding domain is similar to the structure of flavodoxin, whereas the two C-terminal dinucleotide-binding domains are similar to those of ferredoxin-NADP+ reductase (FNR). The connecting domain, situated between the FMN-binding and FNR-like domains, is responsible for the relative orientation of the other domains, ensuring the proper alignment of the two flavins necessary for efficient electron transfer. The two flavin isoalloxazine rings are juxtaposed, with the closest distance between them being about 4 A. The bowl-shaped surface near the FMN-binding site is likely the docking site of cytochrome c and the physiological redox partners, including cytochromes P450 and b5 and heme oxygenase.
Collapse
|
research-article |
28 |
582 |
7
|
Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010; 62:90-9. [PMID: 20380880 DOI: 10.1016/j.phrs.2010.03.005] [Citation(s) in RCA: 575] [Impact Index Per Article: 38.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2010] [Revised: 03/18/2010] [Accepted: 03/19/2010] [Indexed: 12/14/2022]
Abstract
Nanotechnology applications in medicine, termed as nanomedicine, have introduced a number of nanoparticles of variable chemistry and architecture for cancer imaging and treatment. Nanotechnology involves engineering multifunctional devices with dimensions at the nanoscale, similar dimensions as those of large biological vesicles or molecules in our body. These devices typically have features just tens to hundred nanometers across and they can carry one or two detection signals and/or therapeutic cargo(s). One unique class of nanoparticles is designed to do both, providing this way the theragnostic nanoparticles (therapy and diagnosis). Being inspired by physiologically existing nanomachines, nanoparticles are designed to safely reach their target and specifically release their cargo at the site of the disease, this way increasing the drug's tissue bioavailability. Nanoparticles have the advantage of targeting cancer by simply being accumulated and entrapped in tumours (passive targeting). The phenomenon is called the enhanced permeation and retention effect, caused by leaky angiogenetic vessels and poor lymphatic drainage and has been used to explain why macromolecules and nanoparticles are found at higher ratios in tumours compared to normal tissues. Although accumulation in tumours is observed cell uptake and intracellular drug release have been questioned. Polyethyleneglycol (PEG) is used to protect the nanoparticles from the Reticulo-Endothelial System (RES), however, it prevents cell uptake and the required intracellular drug release. Grafting biorecognition molecules (ligands) onto the nanoparticles refers to active targeting and aims to increase specific cell uptake. Nanoparticles bearing these ligands are recognised by cell surface receptors and this leads to receptor-mediated endocytosis. Several materials are suggested for the design of nanoparticles for cancer. Polymers, linear and dendrimers, are associated with the drug in a covalent or non-covalent way and have been used with or without a targeting ligand. Stealth liposomes are suggested to carry the drug in the aqueous core, and they are usually decorated by recognition molecules, being widely studied and applied. Inorganic nanoparticles such as gold and iron oxide are usually coupled to the drug, PEG and the targeting ligand. It appears that the PEG coating and ligand decoration are common constituents in most types of nanoparticles for cancer. There are several examples of successful cancer diagnostic and therapeutic nanoparticles and many of them have rapidly moved to clinical trials. Nevertheless there is still a room for optimisation in the area of the nanoparticle kinetics such as improving their plasma circulation and tumour bioavailability and understanding the effect of targeting ligands on their efficiency to treat cancer. The need to develop novel and efficient ligands has never been greater, and the use of proper conjugation chemistry is mandatory.
Collapse
|
Review |
15 |
575 |
8
|
Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72:9706-13. [PMID: 9811704 PMCID: PMC110480 DOI: 10.1128/jvi.72.12.9706-9713.1998] [Citation(s) in RCA: 574] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Recombinant adenoviruses (Ad) have become the vector system of choice for a variety of gene therapy applications. However, the utility of Ad vectors is limited due to the low efficiency of Ad-mediated gene transfer to cells expressing marginal levels of the coxsackievirus and adenovirus receptor (CAR). In order to achieve CAR-independent gene transfer by Ad vectors in clinically important contexts, we proposed modification of viral tropism via genetic alterations to the viral fiber protein. We have shown that incorporation of an Arg-Gly-Asp (RGD)-containing peptide in the HI loop of the fiber knob domain results in the ability of the virus to utilize an alternative receptor during the cell entry process. We have also demonstrated that due to its expanded tissue tropism, this novel vector is capable of efficient transduction of primary tumor cells. An increase in gene transfer to ovarian cancer cells of 2 to 3 orders of magnitude was demonstrated by the vector, suggesting that recombinant Ad containing fibers with an incorporated RGD peptide may be of great utility for treatment of neoplasms characterized by deficiency of the primary Ad type 5 receptor.
Collapse
|
research-article |
27 |
574 |
9
|
Abstract
A library of overlapping cDNAs obtained from Norwalk virus purified from stools of human volunteers (Jiang et al., 1990, Science 250, 1580-1583) was used to obtain the nucleotide sequence of the viral genome. The sequence has a total of 7642 nucleotides, excluding the 3' poly(A) tail, and has a base composition of 48% G + C. Three open reading frames (ORF) are predicted in the sequence. The longest ORF (ORF1, nucleotides (nt) 146 to 5359) is predicted to encode a polyprotein precursor to nonstructural proteins based on identification of sequences similar to the picornavirus 2C protein, 3C protease, and 3D RNA-dependent RNA polymerase. ORF2 (nt 5346 to 6935) is predicted to encode a polypeptide with a predicted molecular weight of 56,571 (56.6K, close to the expected size of the viral capsid protein), and it contains a short region of sequence similarity to the picornavirus structural protein VP3. A third potential ORF (nt 6938 to 7573) could encode a small polypeptide of 22.5K. The genomic organization found in Norwalk virus shares striking similarities with the genome of two caliciviruses, the feline calicivirus and the rabbit hemorrhagic disease virus. The morphology, size, polarity, and genomic organization of the Norwalk virus indicate it is a member of the Caliciviridae family.
Collapse
|
|
32 |
451 |
10
|
Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271:30375-80. [PMID: 8939999 DOI: 10.1074/jbc.271.48.30375] [Citation(s) in RCA: 404] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
The tissue inhibitors of metalloproteinases (TIMPs) constitute a family of proteins, of which three members have so far been described. Using the expressed sequence tag sequencing approach, we have identified a novel TIMP-related cDNA fragment and subsequently cloned a fourth human TIMP (TIMP-4) from a human heart cDNA library. The open reading frame encodes a 224-amino acid precursor including a 29-residue secretion signal. The predicted structure of the new protein shares 37% sequence identity with TIMP-1 and 51% identity with TIMP-2 and -3. The protein has a predicted isoelectric point of 7.34. The open reading frame-directed expression of TIMP-4 protein in MDA-MB-435 human breast cancer cells showed metalloproteinase inhibitory activity on reverse zymography. By Northern analysis, only the adult heart showed abundant TIMP-4 transcripts with a 1. 4-kilobase predominant transcript band; very low levels of the transcripts were detected in the kidney, placenta, colon, and testes, and no transcripts were detected in the liver, brain, lung, thymus, and spleen. This unique expression pattern suggests that TIMP-4 may function in a tissue-specific fashion in extracellular matrix homeostasis.
Collapse
|
|
29 |
404 |
11
|
Sampson DA, Wang M, Matunis MJ. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J Biol Chem 2001; 276:21664-9. [PMID: 11259410 DOI: 10.1074/jbc.m100006200] [Citation(s) in RCA: 398] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
SUMO-1 is an ubiquitin-related protein that is covalently conjugated to a diverse assortment of proteins. The consequences of SUMO-1 modification include the regulation of protein-protein interactions, protein-DNA interactions, and protein subcellular localization. At present, very little is understood about the specific mechanisms that govern the recognition of proteins as substrates for SUMO-1 modification. However, many of the proteins that are modified by SUMO-1 interact directly with the SUMO-1 conjugating enzyme, Ubc9. These interactions suggest that Ubc9 binding may play an important role in substrate recognition as well as in substrate modification. The SUMO-1 consensus sequence (SUMO-1-CS) is a motif of conserved residues surrounding the modified lysine residue of most SUMO-1 substrates. This motif conforms to the sequence "PsiKXE," where Psi is a large hydrophobic residue, K is the lysine to which SUMO-1 is conjugated, X is any amino acid, and E is glutamic acid. In this study, we demonstrate that the SUMO-1-CS is a major determinant of Ubc9 binding and SUMO-1 modification. Mutating residues in the SUMO-1-CS abolishes both Ubc9 binding and substrate modification. These findings have important implications for how SUMO-1 substrates are recognized and for how SUMO-1 is ultimately transferred to specific lysine residues on these substrates.
Collapse
|
|
24 |
398 |
12
|
Wang M, Weiss M, Simonovic M, Haertinger G, Schrimpf SP, Hengartner MO, von Mering C. PaxDb, a database of protein abundance averages across all three domains of life. Mol Cell Proteomics 2012; 11:492-500. [PMID: 22535208 PMCID: PMC3412977 DOI: 10.1074/mcp.o111.014704] [Citation(s) in RCA: 364] [Impact Index Per Article: 28.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2011] [Revised: 03/26/2012] [Indexed: 02/04/2023] Open
Abstract
Although protein expression is regulated both temporally and spatially, most proteins have an intrinsic, "typical" range of functionally effective abundance levels. These extend from a few molecules per cell for signaling proteins, to millions of molecules for structural proteins. When addressing fundamental questions related to protein evolution, translation and folding, but also in routine laboratory work, a simple rough estimate of the average wild type abundance of each detectable protein in an organism is often desirable. Here, we introduce a meta-resource dedicated to integrating information on absolute protein abundance levels; we place particular emphasis on deep coverage, consistent post-processing and comparability across different organisms. Publicly available experimental data are mapped onto a common namespace and, in the case of tandem mass spectrometry data, re-processed using a standardized spectral counting pipeline. By aggregating and averaging over the various samples, conditions and cell-types, the resulting integrated data set achieves increased coverage and a high dynamic range. We score and rank each contributing, individual data set by assessing its consistency against externally provided protein-network information, and demonstrate that our weighted integration exhibits more consistency than the data sets individually. The current PaxDb-release 2.1 (at http://pax-db.org/) presents whole-organism data as well as tissue-resolved data, and covers 85,000 proteins in 12 model organisms. All values can be seamlessly compared across organisms via pre-computed orthology relationships.
Collapse
|
research-article |
13 |
364 |
13
|
Gordon HR, Wang M. Retrieval of water-leaving radiance and aerosol optical thickness over the oceans with SeaWiFS: a preliminary algorithm. APPLIED OPTICS 1994; 33:443-452. [PMID: 20862036 DOI: 10.1364/ao.33.000443] [Citation(s) in RCA: 345] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The second generation of ocean-color-analyzing instruments requires more accurate atmospheric correction than does the Coastal Zone Color Scanner (CZCS), if one is to utilize fully their increased radiometric sensitivity. Unlike the CZCS, the new instruments possess bands in the near infrared (NIR) that are solely for aiding atmospheric correction. We show, using aerosol models, that certain assumptions regarding the spectral behavior of the aerosol reflectance employed in the standard CZCS correction algorithm are not valid over the spectral range encompassing both the visible and the NIR. Furthermore, we show that multiple-scattering effects on the algorithm depend significantly on the aerosol model. Following these observations, we propose an algorithm that utilizes the NIR bands for atmospheric correction to the required accuracy. Examples of the dependence of the error on the aerosol model, the turbidity of the atmosphere, and surface roughness (waves) are provided. The error in the retrieved phytoplankton-pigment concentration (the principal product of ocean-color sensors) induced by errors in the atmospheric correction are shown to be <20% in approximately 90% of the cases examined. Finally, the aerosol thickness (τ(α)) is estimated through a simple extension of the correction algorithm. Simulations suggest that the error in the recovered value of τ(α) should be ≲ 10%.
Collapse
|
|
31 |
345 |
14
|
Song E, Ouyang N, Hörbelt M, Antus B, Wang M, Exton MS. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol 2000; 204:19-28. [PMID: 11006014 DOI: 10.1006/cimm.2000.1687] [Citation(s) in RCA: 337] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Activated macrophages regulate fibrogenesis by providing cytokines and growth factors that modulate the proliferation and collagen synthesis of fibroblasts. However, macrophages can be activated in a classical pathway induced by LPS or IFN-gamma and an alternative pathway induced by IL-4 or glucocorticoid. Differently activated macrophages display distinct biological features. To clarify the difference between these two subsets of macrophages in the regulatory mechanisms controlling fibrogenesis, human peripheral blood monocytes were used as the source of macrophages and cocultivation of differently activated macrophages and a fibroblast cell line, WI-38, was performed. Alternatively activated macrophages increased the proliferation index and collagen synthesis of cocultivated WI-38 cells in comparison to untreated monocytes, while classically activated macrophages markedly reduced collagen production of cocultivated WI-38 cells. Additionally, mRNA expression and protein production of TGF-beta(1), PDGF-AA, and PDGF-BB were elevated in alternatively activated macrophages in parallel to their profibrogenic effects. In contrast, expression and production of TNF-alpha, as well as MMP-7, were enhanced in classically activated macrophages. These findings suggested that alternatively activated macrophages enhance fibrogenesis of fibroblasts by providing profibrogenic factors, while classically activated macrophages inhibit fibrogenesis of fibroblasts by releasing antifibrogenic or fibrolytic factors.
Collapse
|
Comparative Study |
25 |
337 |
15
|
Abbott BP, Abbott R, Abbott TD, Abernathy MR, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allocca A, Altin PA, Anderson SB, Anderson WG, Arai K, Araya MC, Arceneaux CC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Aufmuth P, Aulbert C, Babak S, Bacon P, Bader MKM, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Barayoga JC, Barclay SE, Barish BC, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Baune C, Bavigadda V, Bazzan M, Bejger M, Bell AS, Berger BK, Bergmann G, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Birch J, Birney R, Birnholtz O, Biscans S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Boer M, Bogaert G, Bogan C, Bohe A, Bond C, Bondu F, Bonnand R, Boom BA, Bork R, Boschi V, Bose S, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brau JE, Briant T, Brillet A, Brinkmann M, Brisson V, Brockill P, Broida JE, Brooks AF, Brown DA, Brown DD, Brown NM, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister T, Calloni E, Camp JB, Cannon KC, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerboni Baiardi L, Cerretani G, Cesarini E, Chamberlin SJ, Chan M, Chao S, Charlton P, Chassande-Mottin E, Cheeseboro BD, Chen HY, Chen Y, Cheng C, Chincarini A, Chiummo A, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua S, Chung S, Ciani G, Clara F, Clark JA, Cleva F, Coccia E, Cohadon PF, Colla A, Collette CG, Cominsky L, Constancio M, Conte A, Conti L, Cook D, Corbitt TR, Cornish N, Corsi A, Cortese S, Costa CA, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Craig K, Creighton JDE, Cripe J, Crowder SG, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Danilishin SL, D'Antonio S, Danzmann K, Darman NS, Dasgupta A, Da Silva Costa CF, Dattilo V, Dave I, Davier M, Davies GS, Daw EJ, Day R, De S, DeBra D, Debreczeni G, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Denker T, Dent T, Dergachev V, De Rosa R, DeRosa RT, DeSalvo R, Devine RC, Dhurandhar S, Díaz MC, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Di Pace S, Di Palma I, Di Virgilio A, Dolique V, Donovan F, Dooley KL, Doravari S, Douglas R, Downes TP, Drago M, Drever RWP, Driggers JC, Ducrot M, Dwyer SE, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Engels W, Essick RC, Etzel T, Evans M, Evans TM, Everett R, Factourovich M, Fafone V, Fair H, Fairhurst S, Fan X, Fang Q, Farinon S, Farr B, Farr WM, Favata M, Fays M, Fehrmann H, Fejer MM, Fenyvesi E, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fisher RP, Flaminio R, Fletcher M, Fong H, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard HAG, Gair JR, Gammaitoni L, Gaonkar SG, Garufi F, Gaur G, Gehrels N, Gemme G, Geng P, Genin E, Gennai A, George J, Gergely L, Germain V, Ghosh A, Ghosh A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gill K, Glaefke A, Goetz E, Goetz R, Gondan L, González G, Gonzalez Castro JM, Gopakumar A, Gordon NA, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Graff PB, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Groot P, Grote H, Grunewald S, Guidi GM, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Hacker JJ, Hall BR, Hall ED, Hamilton H, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Hartman MT, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Henry J, Heptonstall AW, Heurs M, Hild S, Hoak D, Hofman D, Holt K, Holz DE, Hopkins P, Hough J, Houston EA, Howell EJ, Hu YM, Huang S, Huerta EA, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Indik N, Ingram DR, Inta R, Isa HN, Isac JM, Isi M, Isogai T, Iyer BR, Izumi K, Jacqmin T, Jang H, Jani K, Jaranowski P, Jawahar S, Jian L, Jiménez-Forteza F, Johnson WW, Johnson-McDaniel NK, Jones DI, Jones R, Jonker RJG, Ju L, K H, Kalaghatgi CV, Kalogera V, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kasprzack M, Katsavounidis E, Katzman W, Kaufer S, Kaur T, Kawabe K, Kéfélian F, Kehl MS, Keitel D, Kelley DB, Kells W, Kennedy R, Key JS, Khalili FY, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim CW, Kim C, Kim J, Kim K, Kim N, Kim W, Kim YM, Kimbrell SJ, King EJ, King PJ, Kissel JS, Klein B, Kleybolte L, Klimenko S, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Kringel V, Krishnan B, Królak A, Krueger C, Kuehn G, Kumar P, Kumar R, Kuo L, Kutynia A, Lackey BD, Landry M, Lange J, Lantz B, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lebigot EO, Lee CH, Lee HK, Lee HM, Lee K, Lenon A, Leonardi M, Leong JR, Leroy N, Letendre N, Levin Y, Lewis JB, Li TGF, Libson A, Littenberg TB, Lockerbie NA, Lombardi AL, London LT, Lord JE, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lück H, Lundgren AP, Lynch R, Ma Y, Machenschalk B, MacInnis M, Macleod DM, Magaña-Sandoval F, Magaña Zertuche L, Magee RM, Majorana E, Maksimovic I, Malvezzi V, Man N, Mandel I, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markosyan AS, Maros E, Martelli F, Martellini L, Martin IW, Martynov DV, Marx JN, Mason K, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matichard F, Matone L, Mavalvala N, Mazumder N, McCarthy R, McClelland DE, McCormick S, McGuire SC, McIntyre G, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Meidam J, Melatos A, Mendell G, Mercer RA, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Mezzani F, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller A, Miller BB, Miller J, Millhouse M, Minenkov Y, Ming J, Mirshekari S, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moggi A, Mohan M, Mohapatra SRP, Montani M, Moore BC, Moore CJ, Moraru D, Moreno G, Morriss SR, Mossavi K, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Murphy DJ, Murray PG, Mytidis A, Nardecchia I, Naticchioni L, Nayak RK, Nedkova K, Nelemans G, Nelson TJN, Neri M, Neunzert A, Newton G, Nguyen TT, Nielsen AB, Nissanke S, Nitz A, Nocera F, Nolting D, Normandin MEN, Nuttall LK, Oberling J, Ochsner E, O'Dell J, Oelker E, Ogin GH, Oh JJ, Oh SH, Ohme F, Oliver M, Oppermann P, Oram RJ, O'Reilly B, O'Shaughnessy R, Ottaway DJ, Overmier H, Owen BJ, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Paris HR, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patricelli B, Patrick Z, Pearlstone BL, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pitkin M, Poe M, Poggiani R, Popolizio P, Post A, Powell J, Prasad J, Predoi V, Prestegard T, Price LR, Prijatelj M, Principe M, Privitera S, Prix R, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Qin J, Qiu S, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rakhmanov M, Rapagnani P, Raymond V, Razzano M, Re V, Read J, Reed CM, Regimbau T, Rei L, Reid S, Reitze DH, Rew H, Reyes SD, Ricci F, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano JD, Romano R, Romanov G, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Sachdev S, Sadecki T, Sadeghian L, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sanchez EJ, Sandberg V, Sandeen B, Sanders JR, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter OES, Savage RL, Sawadsky A, Schale P, Schilling R, Schmidt J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schutz BF, Scott J, Scott SM, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer T, Shahriar MS, Shaltev M, Shapiro B, Shawhan P, Sheperd A, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer A, Singer LP, Singh A, Singh R, Singhal A, Sintes AM, Slagmolen BJJ, Smith JR, Smith ND, Smith RJE, Son EJ, Sorazu B, Sorrentino F, Souradeep T, Srivastava AK, Staley A, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stephens BC, Stevenson SP, Stone R, Strain KA, Straniero N, Stratta G, Strauss NA, Strigin S, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Talukder D, Tanner DB, Tápai M, Tarabrin SP, Taracchini A, Taylor R, Theeg T, Thirugnanasambandam MP, Thomas EG, Thomas M, Thomas P, Thorne KA, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tomlinson C, Tonelli M, Tornasi Z, Torres CV, Torrie CI, Töyrä D, Travasso F, Traylor G, Trifirò D, Tringali MC, Trozzo L, Tse M, Turconi M, Tuyenbayev D, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Vass S, Vasúth M, Vaulin R, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Verkindt D, Vetrano F, Viceré A, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Voss DV, Vousden WD, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang M, Wang X, Wang Y, Ward RL, Warner J, Was M, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wen L, Weßels P, Westphal T, Wette K, Whelan JT, Whiting BF, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Worden J, Wright JL, Wu DS, Wu G, Yablon J, Yam W, Yamamoto H, Yancey CC, Yu H, Yvert M, Zadrożny A, Zangrando L, Zanolin M, Zendri JP, Zevin M, Zhang L, Zhang M, Zhang Y, Zhao C, Zhou M, Zhou Z, Zhu XJ, Zucker ME, Zuraw SE, Zweizig J, Boyle M, Hemberger D, Kidder LE, Lovelace G, Ossokine S, Scheel M, Szilagyi B, Teukolsky S. GW151226: Observation of Gravitational Waves from a 22-Solar-Mass Binary Black Hole Coalescence. PHYSICAL REVIEW LETTERS 2016; 116:241103. [PMID: 27367379 DOI: 10.1103/physrevlett.116.241103] [Citation(s) in RCA: 282] [Impact Index Per Article: 31.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Indexed: 05/21/2023]
Abstract
We report the observation of a gravitational-wave signal produced by the coalescence of two stellar-mass black holes. The signal, GW151226, was observed by the twin detectors of the Laser Interferometer Gravitational-Wave Observatory (LIGO) on December 26, 2015 at 03:38:53 UTC. The signal was initially identified within 70 s by an online matched-filter search targeting binary coalescences. Subsequent off-line analyses recovered GW151226 with a network signal-to-noise ratio of 13 and a significance greater than 5σ. The signal persisted in the LIGO frequency band for approximately 1 s, increasing in frequency and amplitude over about 55 cycles from 35 to 450 Hz, and reached a peak gravitational strain of 3.4_{-0.9}^{+0.7}×10^{-22}. The inferred source-frame initial black hole masses are 14.2_{-3.7}^{+8.3}M_{⊙} and 7.5_{-2.3}^{+2.3}M_{⊙}, and the final black hole mass is 20.8_{-1.7}^{+6.1}M_{⊙}. We find that at least one of the component black holes has spin greater than 0.2. This source is located at a luminosity distance of 440_{-190}^{+180} Mpc corresponding to a redshift of 0.09_{-0.04}^{+0.03}. All uncertainties define a 90% credible interval. This second gravitational-wave observation provides improved constraints on stellar populations and on deviations from general relativity.
Collapse
|
|
9 |
282 |
16
|
Pandit JJ, Andrade J, Bogod DG, Hitchman JM, Jonker WR, Lucas N, Mackay JH, Nimmo AF, O'Connor K, O'Sullivan EP, Paul RG, Palmer JHMG, Plaat F, Radcliffe JJ, Sury MRJ, Torevell HE, Wang M, Hainsworth J, Cook TM. 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: summary of main findings and risk factors. Br J Anaesth 2014; 113:549-59. [PMID: 25204697 DOI: 10.1093/bja/aeu313] [Citation(s) in RCA: 282] [Impact Index Per Article: 25.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
We present the main findings of the 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia (AAGA). Incidences were estimated using reports of accidental awareness as the numerator, and a parallel national anaesthetic activity survey to provide denominator data. The incidence of certain/probable and possible accidental awareness cases was ~1:19,600 anaesthetics (95% confidence interval 1:16,700-23,450). However, there was considerable variation across subtypes of techniques or subspecialities. The incidence with neuromuscular block (NMB) was ~1:8200 (1:7030-9700), and without, it was ~1:135,900 (1:78,600-299,000). The cases of AAGA reported to NAP5 were overwhelmingly cases of unintended awareness during NMB. The incidence of accidental awareness during Caesarean section was ~1:670 (1:380-1300). Two-thirds (82, 66%) of cases of accidental awareness experiences arose in the dynamic phases of anaesthesia, namely induction of and emergence from anaesthesia. During induction of anaesthesia, contributory factors included: use of thiopental, rapid sequence induction, obesity, difficult airway management, NMB, and interruptions of anaesthetic delivery during movement from anaesthetic room to theatre. During emergence from anaesthesia, residual paralysis was perceived by patients as accidental awareness, and commonly related to a failure to ensure full return of motor capacity. One-third (43, 33%) of accidental awareness events arose during the maintenance phase of anaesthesia, mostly due to problems at induction or towards the end of anaesthesia. Factors increasing the risk of accidental awareness included: female sex, age (younger adults, but not children), obesity, anaesthetist seniority (junior trainees), previous awareness, out-of-hours operating, emergencies, type of surgery (obstetric, cardiac, thoracic), and use of NMB. The following factors were not risk factors for accidental awareness: ASA physical status, race, and use or omission of nitrous oxide. We recommend that an anaesthetic checklist, to be an integral part of the World Health Organization Safer Surgery checklist, is introduced as an aid to preventing accidental awareness. This paper is a shortened version describing the main findings from NAP5--the full report can be found at http://www.nationalauditprojects.org.uk/NAP5_home.
Collapse
|
Research Support, Non-U.S. Gov't |
11 |
282 |
17
|
Ehlers CL, Henriksen SJ, Wang M, Rivier J, Vale W, Bloom FE. Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Res 1983; 278:332-6. [PMID: 6605787 DOI: 10.1016/0006-8993(83)90266-4] [Citation(s) in RCA: 267] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Corticotropin releasing factor (CRF) is a 41-residue peptide, capable of stimulating the secretion of corticotropin (ACTH)-like and beta-endorphin-like immunoreactivity from the adenohypophysis. Low doses of CRF (0.0015-0.15 nM) given intracerebroventricularly (i.c.v.) produced changes in electrographic activity suggestive of increased arousal. Higher doses of CRF (1.5-3.75 nM) induced, over a period of 3-7 h, electrographic and behavioral signs of seizure activity indistinguishable from those which occur following electrical 'kindling' of the amygdala.
Collapse
|
|
42 |
267 |
18
|
Yip G, Wang M, Zhang Y, Fung JWH, Ho PY, Sanderson JE. Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition? Heart 2002; 87:121-5. [PMID: 11796546 PMCID: PMC1766981 DOI: 10.1136/heart.87.2.121] [Citation(s) in RCA: 253] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
OBJECTIVE To test the hypothesis that, when measured in the long axis, left ventricular systolic function is abnormal in patients with diastolic heart failure. DESIGN A case-control study. SETTING University teaching hospital (tertiary referral centre). PATIENTS 68 patients with heart failure, 29 with a left ventricular ejection fraction (LVEF) of > 0.45 and diastolic dysfunction (diastolic heart failure), 39 with an LVEF of </= 0.45 (systolic heart failure), and 105 normal subjects, including 33 age matched controls. METHODS LVEF was measured by cross sectional Simpson's method, and mitral annular amplitudes and velocities by M mode and tissue Doppler echocardiography, respectively, along with mitral Doppler inflow velocities. Results were compared between the three groups. MAIN OUTCOME MEASURES Peak systolic mitral annular velocity and amplitude between the different groups. RESULTS The mitral annular peak mean velocity and amplitude in systole were lower in the patients with diastolic heart failure (mean (SEM), 4.8 (0.2) cm/s) than in the age matched normal controls (6.1 (0.14) cm/s), but higher than those with systolic heart failure (2.8 (0.13) cm/s) (all p < 0.001). Similar changes were seen the mitral annular amplitude during systole. Peak early diastolic velocity and amplitude were also significantly reduced in the group with diastolic heart failure. Left ventricular hypertrophy was evident in over 95% patients in both diastolic and systolic heart failure groups, with a comparable left ventricular mass index. CONCLUSIONS In patients with diastolic heart failure and evidence of left ventricular hypertrophy, there is systolic left ventricular impairment as measured by myocardial Doppler imaging of the longitudinal axis. Thus subtle abnormalities of systolic function are present in patients with heart failure and a normal left ventricular ejection fraction, and there appears to be a continuum of systolic function between those with truly normal, mildly impaired (labelled diastolic heart failure), and obviously abnormal left ventricular systolic function. Isolated diastolic dysfunction is uncommon.
Collapse
|
research-article |
23 |
253 |
19
|
Saliba D, Kington R, Buchanan J, Bell R, Wang M, Lee M, Herbst M, Lee D, Sur D, Rubenstein L. Appropriateness of the decision to transfer nursing facility residents to the hospital. J Am Geriatr Soc 2000; 48:154-63. [PMID: 10682944 DOI: 10.1111/j.1532-5415.2000.tb03906.x] [Citation(s) in RCA: 252] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVES To develop and test a standardized instrument, the purpose of which is to assess (1) whether skilled nursing facilities (SNFs) transfer residents to emergency departments (ED) inappropriately, (2) whether residents are admitted to hospitals inappropriately, (3) and factors associated with inappropriate transfers. DESIGN A structured implicit review (SIR) of medical records. SETTING AND PARTICIPANTS Using nested random sampling in eight community SNFs, we identified SNF and hospital records of 100 unscheduled transfers to one of 10 hospitals. MEASUREMENTS Seven trained physician reviewers assessed appropriateness using a SIR form designed for this study (2 independent reviews per record, 200 total reviews). We measured interrater reliability with kappa statistics and used bivariate analysis to identify factors associated with assessment that transfer was inappropriate. RESULTS In 36% of ED transfers and 40% of hospital admissions, both reviewers agreed that transfer/admit was inappropriate, meaning the resident could have been cared for safely at a lower level of care. Agreement was high for both ED (percent agreement 84%, kappa .678) and hospital (percent agreement 89%, kappa .779). When advance directives were considered, both reviewers rated 44% of ED transfers and 45% of admissions inappropriate. Factors associated with inappropriateness included the perceptions that: (1) poor quality of care contributed to transfer need, (2) needed services would typically be available in outpatient settings, and (3) the chief complaint did not warrant hospitalization. CONCLUSIONS Inappropriate transfers are a potentially large problem. Some inappropriate transfers may be associated with poor quality of care in SNFs. This study demonstrates that structured implicit review meets criteria for reliable assessment of inappropriate transfer rates. Structured implicit review may be a valuable tool for identifying inappropriate transfers from SNFs to EDs and hospitals.
Collapse
|
|
25 |
252 |
20
|
Bass LA, Wang M, Welch MJ, Anderson CJ. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem 2000; 11:527-32. [PMID: 10898574 DOI: 10.1021/bc990167l] [Citation(s) in RCA: 238] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
An understanding of the metabolic fate of radiometal-labeled peptides is important due to their application in the areas of diagnostic imaging and targeted radiotherapy. Radioisotopes of copper ((64)Cu, T(1/2) = 12.7 h; (67)Cu, T(1/2) = 62 h) have been labeled to monoclonal antibodies (mAbs) and peptides and have applications in the areas of PET imaging and targeted radiotherapy of cancer. Copper-64-TETA-D-Phe(1)-octreotide ([(64)Cu]TETA-OC) has been shown to bind to the somatostatin receptor, both in vitro and in vivo, and this agent inhibited the growth of somatostatin-receptor positive tumors in rats. Copper-64-TETA-OC, however, showed a retention of activity in the blood, liver, and bone marrow, suggesting possible dissociation of (64)Cu from TETA-OC in vivo. The purpose of this study was to determine if (64)Cu dissociates from [(64)Cu]TETA-OC and binds to the protein, superoxide dismutase (SOD) in rat liver. The liver metabolism of [(64)Cu]TETA-OC was examined in normal rats using a gel-electrophoresis assay specific for SOD and size-exclusion chromatography. The major metabolite in rat liver at 20 h postinjection had a molecular weight of 32 kDa as shown by size-exclusion chromatography. A gel electrophoresis assay specific for the detection of SOD [nitro-blue tetrazolium (NBT)] showed that a (64)Cu-labeled protein isolated from rat liver homogenates comigrated with SOD. Evaluating the metabolic fate of copper radiopharmaceuticals demonstrated that Cu(II) dissociates from macrocyclic chelators such as TETA and binds to proteins in high concentrations, namely SOD in rat liver.
Collapse
|
|
25 |
238 |
21
|
Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, Jones LA, Cohen AS. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100:290-8. [PMID: 8629674 DOI: 10.1016/s0002-9343(97)89487-9] [Citation(s) in RCA: 235] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
PURPOSE A clinical trial designed to test whether treatment with melphalan, prednisone, and colchicine (MPC) is superior to colchicine (C) alone was performed in patients with primary amyloidosis (AL), a nonmalignant plasma cell dyscrasia. PATIENTS AND METHODS Patients were randomized to MPC or C with stratification according to sex, time from diagnosis to study entry (ie, less than 3 months or 3 to 12 months), and dominant organ system involvement (ie, cardiac, renal, neurologic, or others). Data were gathered monthly from patients, quarterly from physicians, and annually in the Clinical Research Center. One hundred consecutive patients with AL amyloidosis admitted between 1987 and 1992 who met eligibility requirements were treated and followed for a minimum of 18 months. Fifty patients (group A) received daily oral colchicine and 50 patients (group B) received cycles of oral melphalan and prednisone every 6 weeks for 1 year as well as colchicine. RESULTS The principal outcome measure was median survival, which was compared in the two treatment groups and in the subgroups. The overall survival of all patients from study entry was 8.4 months. Comparing group A (C) to group B (MPC), the survival was 6.7 months versus 12.2 months (P = 0.087). Both treatment groups had poor survival for patients in the cardiac subgroup, longest survival in the renal group, and significant differences favoring MPC treatment only in patients whose major system manifestations were neurologic (P = 0.037) or other (P = 0.007). Multivariate analysis showed a strongly significant treatment effect (P = 0.003) and improved survival associated with not having cardiac or gastrointestinal involvement. CONCLUSIONS MPC was advantageous for patients whose major manifestations of amyloid disease were other than cardiac or renal. Better survival regardless of treatment was noted in patients for whom a satisfactory supportive treatment such as transplant or dialysis exists for their organ failure.
Collapse
|
Clinical Trial |
29 |
235 |
22
|
Nelson HH, Wiencke JK, Christiani DC, Cheng TJ, Zuo ZF, Schwartz BS, Lee BK, Spitz MR, Wang M, Xu X. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995; 16:1243-5. [PMID: 7767992 DOI: 10.1093/carcin/16.5.1243] [Citation(s) in RCA: 230] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
In humans the glutathione S-transferase (GST) genes encode four classes of proteins (GST) important in the detoxification of reactive electrophiles. Recently, a gene deletion polymorphism was discovered within the GST class theta locus that leads to a functional deficiency in GST theta activity within circulating red blood cells. In this study we have examined the ethnic distribution of this polymorphism using a polymerase chain reaction (PCR)-based genotyping method. Five different ethnic groups were studied: North American Caucasians, African-Americans, Mexican-Americans, Chinese and Koreans. The prevalence of the null genotype was highest among Chinese (64.4%), followed by Koreans (60.2%), African-Americans (21.8%) and Caucasians (20.4%), whereas the prevalence was lowest among Mexican-Americans (9.7%). Interestingly, the prevalence of the deleted genotype in Caucasians differed significantly when 257 individuals drawn from a nation wide organization were compared with 185 people from the New England area (23.7 versus 15.7%, P < 0.05, chi 2 test). These results indicate that there are major differences in the prevalence of this trait attributable to ethnicity and that ethnic origin even among Caucasians should be considered in studies of gene-environment interaction involving this polymorphism.
Collapse
|
Comparative Study |
30 |
230 |
23
|
Zhang Y, Yuan F, Wu X, Wang M, Rechkoblit O, Taylor JS, Geacintov NE, Wang Z. Error-free and error-prone lesion bypass by human DNA polymerase kappa in vitro. Nucleic Acids Res 2000; 28:4138-46. [PMID: 11058110 PMCID: PMC113145 DOI: 10.1093/nar/28.21.4138] [Citation(s) in RCA: 230] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2000] [Revised: 09/13/2000] [Accepted: 09/13/2000] [Indexed: 11/12/2022] Open
Abstract
Error-free lesion bypass and error-prone lesion bypass are important cellular responses to DNA damage during replication, both of which require a DNA polymerase (Pol). To identify lesion bypass DNA polymerases, we have purified human Polkappa encoded by the DINB1 gene and examined its response to damaged DNA templates. Here, we show that human Polkappa is a novel lesion bypass polymerase in vitro. Purified human Polkappa efficiently bypassed a template 8-oxoguanine, incorporating mainly A and less frequently C opposite the lesion. Human Polkappa most frequently incorporated A opposite a template abasic site. Efficient further extension required T as the next template base, and was mediated mainly by a one-nucleotide deletion mechanism. Human Polkappa was able to bypass an acetylaminofluorene-modified G in DNA, incorporating either C or T, and less efficiently A opposite the lesion. Furthermore, human Polkappa effectively bypassed a template (-)-trans-anti-benzo[a]pyrene-N:(2)-dG lesion in an error-free manner by incorporating a C opposite the bulky adduct. In contrast, human Polkappa was unable to bypass a template TT dimer or a TT (6-4) photoproduct, two of the major UV lesions. These results suggest that Polkappa plays an important role in both error-free and error-prone lesion bypass in humans.
Collapse
|
research-article |
25 |
230 |
24
|
Wang M, Hettiarachchy NS, Qi M, Burks W, Siebenmorgen T. Preparation and functional properties of rice bran protein isolate. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 1999; 47:411-416. [PMID: 10563909 DOI: 10.1021/jf9806964] [Citation(s) in RCA: 227] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Rice bran protein isolate (RBPI) containing approximately 92.0% protein was prepared from unstabilized and defatted rice bran using phytase and xylanase. The yield of RBPI increased from 34% to 74.6% through the use of the enzymatic treatment. Nitrogen solubilities of RBPI were 53, 8, 62, 78, 82, and 80% at pHs 2.0, 4.0, 6.0, 8.0, 10.0, and 12.0, respectively. Differential scanning calorimetry showed that RBPI had denaturation temperature of 83.4 degrees C with low endotherm (0.96 J/g of protein). RBPI had similar foaming properties in comparison to egg white. But emulsifying properties of RBPI were significantly lower than those of bovine serum albumin. The result of amino acid analysis showed that RBPI had a similar profile of essential amino acid requirements for 2-5-year-old children in comparison to that of casein and soy protein isolate.
Collapse
|
|
26 |
227 |
25
|
Birnbaum SG, Yuan PX, Wang M, Vijayraghavan S, Bloom AK, Davis DJ, Gobeske KT, Sweatt JD, Manji HK, Arnsten AFT. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 2004; 306:882-4. [PMID: 15514161 DOI: 10.1126/science.1100021] [Citation(s) in RCA: 226] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The prefrontal cortex is a higher brain region that regulates thought, behavior, and emotion using representational knowledge, operations often referred to as working memory. We tested the influence of protein kinase C (PKC) intracellular signaling on prefrontal cortical cognitive function and showed that high levels of PKC activity in prefrontal cortex, as seen for example during stress exposure, markedly impair behavioral and electrophysiological measures of working memory. These data suggest that excessive PKC activation can disrupt prefrontal cortical regulation of behavior and thought, possibly contributing to signs of prefrontal cortical dysfunction such as distractibility, impaired judgment, impulsivity, and thought disorder.
Collapse
|
Research Support, U.S. Gov't, P.H.S. |
21 |
226 |